Rising Brand-Name Drug Prices in the US: A Global Perspective
Decision brief
Answer first · skim in under a minute
This article examines the trend of increasing brand-name drug prices in the US compared to declining prices abroad, highlighting the implications for pharmaceutical companies.
Rising Brand-Name Drug Prices in the US: A Global Perspective is now a board-level problem as HHS Most-Favored-Nation targets push U.S. list and net prices toward the lowest peer OECD levels.
Contents11 sections
Key Takeaways
- On May 20, 2025, HHS said MFN targets aim to align U.S. brand prices with the lowest price in OECD peers with GDP per capita at least 60% of the U.S.
- HHS stated U.S. prices are often three to five times higher than prices abroad for the same brands.
- Reuters reported President Trump’s May 12, 2025 order sought cuts of roughly 59% to 90% if manufacturers miss targets.
- CMS extended the voluntary GENEROUS Medicaid model application deadline to April 30, 2026.
What is the Most Favored Nation drug pricing push?
HHS and CMS announced on May 20, 2025 that they are implementing the executive order on Most-Favored-Nation prescription drug pricing for American patients.
Manufacturers are expected to align U.S. pricing for brand products without generic or biosimilar competition to the lowest price in a set of economic peer countries.
How large is the US versus global price gap?
The HHS release said U.S. drug prices are often three to five times higher than prices abroad. A May 12, 2025 Reuters report said the White House was seeking cuts of between 59% and 90% if industry does not make significant progress.
That gap is why EU and UK net prices increasingly set a ceiling that U.S. payers and policymakers want to import.
How does CMS operationalize international reference pricing?
CMS documentation on the prior MFN Model explains the GDP-adjusted OECD peer formula that later policy rhetoric still echoes: lowest adjusted price among OECD members with GDP per capita at least 60% of the U.S.
The 2020 mandatory Part B model was blocked in court and never implemented, which is why the 2025 approach mixes executive pressure, voluntary Medicaid tools, and threatened rulemaking.
- Peer filter: OECD + ≥60% U.S. GDP per capita
- HHS gap claim: 3–5× U.S. vs abroad
- GENEROUS deadline: April 30, 2026
What should EU launch teams change now?
If U.S. net prices must track the lowest peer country, early EU confidential discounts become a global transfer-price risk. CMS’s GENEROUS Model lets participating Medicaid programs buy included drugs at prices closer to select other countries.
Pricing committees should model launch sequence, indication sequencing, and rebate corridors with a binding international floor—not a U.S.-first premium that can be clawed back later.
What remains uncertain for commercial strategy
Executive targets are not yet a fully litigated, nationwide Part B payment rule. Analysts quoted by Reuters questioned enforceability. Parallel trade, reference-price spillover, and state Medicaid uptake of GENEROUS will decide real revenue impact before 2027.
Implications for licensing and market access
Deal models that assumed durable U.S. list-price growth now need downside cases. BD teams should reopen royalty stacks and co-pay programs when ex-U.S. net prices can pull U.S. revenue down.
How Rising Brand-Name Drug Prices in the US reshape EU filings
Rising Brand-Name Drug Prices in the US: A Global Perspective forces European affiliates to treat every confidential discount as a potential future U.S. ceiling. Launch sequencing that once maximized U.S. list price first now needs a global net-price corridor agreed before CHMP opinion.
Market-access leads should rebuild forecast models with three cases: voluntary manufacturer alignment to MFN targets, Medicaid GENEROUS uptake in large states, and contested rulemaking that stalls into 2027. Each case changes royalty waterfalls on ex-U.S. licenses differently.
Parallel trade monitoring intensifies when U.S.–EU spreads compress. Wholesalers chase remaining gaps; compliance teams should refresh pedigree and diversion controls rather than assume policy alone closes arbitrage.
Investors will punish guidance that still assumes mid-single-digit U.S. brand price growth without an MFN downside. CFOs should disclose sensitivity tables before the next earnings season rather than after an HHS naming campaign.
Related NovaPharma coverage
- MFN drug pricing reshapes licensing deals
- India-Oman CEPA and export barriers
- Novel muscle-active agents regulatory view
Frequently Asked Questions
What MFN target did HHS describe in May 2025?
HHS said manufacturers should align U.S. pricing for brand products without generic or biosimilar competition with the lowest price in OECD peer countries that have GDP per capita of at least 60% of the U.S.
How much higher did HHS say U.S. prices are versus abroad?
HHS stated that U.S. drug prices are often three to five times higher than prices abroad for the same medicines.
What is the GENEROUS Model deadline CMS extended?
CMS extended the manufacturer application deadline for the GENEROUS Medicaid model from March 31, 2026, to April 30, 2026.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
